VIDA Completes Second Close Of Round C Financing

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

VIDA Diagnostics, Inc. (“VIDA”), the leader in AI-powered lung imaging analysis, received $2M from OSF Ventures, the corporate investment arm of OSF HealthCare, as the second close of its C round funding. This investment augments an $11M investment round last month led by First Analysis Corporation and will further fuel the development and commercialization of VIDA’s innovative solutions to impact patient care for both traditional respiratory diseases as well as emergent COVID-19 conditions.

“OSF is an ideal strategic partner for VIDA.  Through both capital and access to clinic leaders, OSF is a catalyst in expanding the footprint of our FDA-approved, AI-powered imaging solutions in this growing market,” said Susan A. Wood, Ph.D., and CEO for VIDA. “Providing access to analysis like LungPrint has never been more important, given the global COVID-19 pandemic on top of an already growing trend of chronic respiratory and lung diseases.”

“We invest in leading-edge solutions that make an immediate impact for OSF Healthcare’s care teams and patients,” said Garrett Vygantas, MD, Managing Director at OSF Ventures. “VIDA’s LungPrint solution helps radiologists and pulmonologists gain valuable insight into each patient’s unique condition, which determines the appropriate treatment plan. We see real value for this new technology to help treat patients with COPD, lung cancer and other pulmonary diseases -and we anticipate LungPrint will help us in the future manage new populations experiencing COVID-19 and determine appropriate follow up and long-term care.”

LungPrint® is an AI-powered suite of products and services used to uniquely profile and manage the patient with or at risk of respiratory and lung diseases. LungPrint provides clinically validated imaging analysis to healthcare providers and clinical trial partners to obtain a more precise, personalized profile of respiratory and lung health.  LungPrint is clinically cleared in the US (FDA 510(k)), EU (CE), Australia (TGA) & Canada (CMDCAS).

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.